Extrait

A consistent finding in many studies in patients with operable esophageal and gastro-esophageal junction (GEJ) cancer is that response to preoperative therapy, particularly the absence of residual disease in the surgical specimen, is an indicator of better disease-free and overall survival. Therefore in our trial we will evaluate the pathologic response of panitumumab in combination with neoadjuvant chemoradiation as first line treatment of operable adenocarcinomas, undifferentiated or squamous cell carcinomas of the esophagus.

Critère d'inclusion

• Surgical resectable: T2-3, N0-1, M0 adenocarcinomas, undifferentiated or squamous cell carcinomas of the esophagus

Liens

• ictrp
• euctr